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ABSTRACT
Vertebral osteomyelitis caused by non-tuberculous mycobacteria is a rare disease, with only 31 cases and
one nosocomial outbreak reported in the literature (MedLine review between 1965 and December 2003).
The clinical features are often indistinguishable from those of pyogenic osteomyelitis. Early diagnosis of
such infections is a major challenge because of the slow growth of these microorganisms. No consensus
guidelines for the treatment of these infections exist. Prolonged anti-mycobacterial therapy in
combination with surgical debridement is recommended.
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Non-tuberculous mycobacteria (NTM) comprise a
group of > 50 different species. They are found
ubiquitously, but with marked geographical vari-
ation, in water, soil and animals (including birds).
Direct transmission from animals is not important
in human infections [1], and human-to-human
transmission appears to be rare. Studies in the
USA between 1980 and 1992 indicate that isolates
of NTM have become more prevalent in recent
years [2]. However, an increase in associated
diseases has not been shown in immunocompe-
tent patients.
Six major clinical syndromes caused by NTM
can be differentiated, of which the most important
is pulmonary infection, presenting either as cavi-
tary disease or as nodular infiltrates. Other syn-
dromes include: local non-tender lymphadenitis;
skin and soft tissue infections, with reported
water-associated nosocomial outbreaks [3]; dis-
seminated infection (> 95% associated with the
Mycobacterium avium complex) in AIDS patients;
and, rarely, catheter-related infections. Finally,
chronic granulomatous infections of bursae, joints,
tendon sheaths and bones are seen after direct
inoculation of NTM through accidental trauma,
surgical incisions, puncture wounds or injections.
Vertebral osteomyelitis (VO) caused by NTM is a
very rare disease. A MedLine review of the litera-
ture between 1965 and December 2003 revealed
only 31 case reports and one nosocomial outbreak
[4–14]. The NTM species identified most frequently
was M. avium complex (n = 13); this was followed
by Mycobacterium xenopi (n = 7), Mycobacterium
fortuitum (n = 5), and Mycobacterium abscessus
(n = 3); there were also single cases involving
Mycobacterium kansasii, Mycobacterium simiae and
one unidentified non-tuberculous mycobacterium.
The mean age of patients was 43 years (range
16–79 years), and there were 19 females and
13 males. Thoracic (n = 15) and lumbar spine
(n = 11) were the most frequent sites of involve-
ment; four cases with multifocal and three with
thoracolumbar involvement were reported.
Unlike other bone and joint infections caused
by NTM, it is unusual for VO to result from
direct inoculation following penetrating trauma,
surgical incision or injections. A genetic defect of
the interferon-c receptor with decreased in-vitro
responsiveness of macrophages to interferon-c
was described in three patients with multifocal
osteomyelitis [9]. A recent hypothesis postulated
a ‘locus minoris resistentiae’ after non-penetrat-
ing trauma as a risk factor [6]. Macrophages
containing NTM could migrate to the region of a
recent trauma, release mycobacteria and initiate
a new focus of infection. A similar pathogenesis
has been reported for tuberculous spondylitis
[15].
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An environmental reservoir, especially water,
is the most likely source of infection, either via
inhalation of contaminated aerosols (e.g., whirl-
pools) or by invasion through the gastrointestinal
tract [16,17]. Strains of the M. avium complex with
plasmids, possibly associated with virulence,
have been shown to be aerosolised preferentially
[18]. A nosocomial outbreak of M. xenopi spinal
infections affecting > 50 patients after discoverte-
bral surgery occurred in the 1990s in France [14].
However, positive identification of M. xenopi must
be interpreted in the clinical context, because
contamination with associated pseudo-outbreaks
has been reported [19].
With the exception of Mycobacterium chelonae
and Mycobacterium haemophilum, which may
involve bones and joints, as well as being found
in nodular skin lesions and bacteraemia in AIDS
patients, most patients with disease of bones,
joints and tendon sheaths caused by NTM do not
have underlying immunosuppression. In contrast,
various degrees of immunosuppression (systemic
lupus erythematosus with steroids, n = 7; HIV
infection, n = 4; interferon receptor defect, n = 3;
carcinoma, n = 1; renal failure, n = 1; and chronic
granulomatous disease, n = 1) were found in 17
(51.5%) of 33 patients with VO caused by NTM.
This difference might be explained by the differ-
ent mode of acquisition of NTM in VO (haema-
togenic, lymphogenic) compared to other skeletal
infections associated with these microorganisms
(direct inoculation).
Two immunocompetent patients with VO
caused by NTM were treated recently at our
institution. The first patient, a man aged 47 years
from Pakistan with a 3-month history of progres-
sive lumbar back pain, had L1–L3 spondylodiscitis
with paravertebral abscesses. Percutaneous trans-
pedicular bone biopsy revealed necrosis without
granulomas or bacteria, or acid-fast bacilli in the
direct smear. Open surgery, with anterior debride-
ment of the abscesses and bone grafting with
posterior transpedicular fixation, revealed gra-
nulomas with multinuclear histiocytic giant cells
and necrosis. Culture of the biopsies for 5–9 weeks
yielded M. xenopi. The second patient, a woman
aged 56 years with a 6-month history of progres-
sive lumbar back pain and slow onset of pleuritic
chest pain, had pleural empyema of the right
hemithorax and an osteolytic lesion at T8 on
computed tomography scan. Open biopsy revealed
necrosis and non-specific granulation tissue with
multinuclear histiocytic giant cells. T8 open lam-
inectomy and debridement showed caseous
necrosis. After 3 weeks, mycobacterial cultures
yielded an isolate of the M. avium complex from
multiple biopsies. The times from first symptoms
to diagnosis for these patients were 16 and
22 weeks, respectively. Treatment with a clarith-
romycin-containing regimen, combined with
surgical debridement, resulted in a favourable
outcome for both patients during the initial fol-
low-up period of 12 months after therapy.
For patients infected with slow-growing bac-
teria such as NTM, early diagnosis is a major
challenge. Multiple cultures of bone biopsy spec-
imens are required. Blood cultures are usually
negative, as is also true for other infections caused
by NTM in immunocompetent patients. Even
with pyogenic VO, only 28% of episodes are
diagnosed within the first month following the
onset of symptoms, and diagnostic delay in these
patients is an independent risk factor for an
unfavourable outcome [20]. VO may have serious
consequences. In pyogenic VO (only one reported
patient with NTM), residual disability occurred in
more than one-third of the survivors, and relapse
occurred in 14% [20]. Corresponding data for VO
caused by NTM are not available.
No consensus guidelines concerning the treat-
ment of spinal infections caused by NTM exist. In
general, NTM are more resistant to anti-tubercu-
lous drugs, and resistance testing in vitro is not
effective in predicting the clinical response. Pro-
longed therapy in combination with surgical
debridement is recommended strongly for all
cases of VO caused by NTM, especially in patients
with abscess formation.
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